CXCL12 and pancreatic neoplasm: In this regard, a recent publication demonstrated that targeting CXCL12 from FAP-expressing CAFs with AMD3100 (Plerixafor) synergizes with anti-PD-L1 immunotherapy in pancreatic cancer (130).